{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:56:01Z","timestamp":1791320161511,"version":"4.3.1"},"reference-count":33,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2024,8,27]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Gantenerumab is an anti-amyloid-\u03b2 immunoglobulin G1 monoclonal antibody for subcutaneous (SC) administration. The efficacy and safety of low-dose (105\u200amg or 225\u200amg) gantenerumab were investigated in Marguerite RoAD (MR; NCT02051608), a Phase III, double-blind (DB), placebo-controlled study in participants with mild Alzheimer\u2019s disease (AD) dementia. Following a preplanned futility analysis of the SCarlet RoAD study (NCT01224106), MR was converted into an open-label extension (OLE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The DB study aimed to assess the efficacy of gantenerumab compared with placebo from baseline to Week 104 in participants with mild AD dementia. Following conversion to an OLE, this objective became exploratory, as the OLE assessed the long-term safety and tolerability of SC gantenerumab at doses of up to 1,200\u200amg every 4 weeks (Q4W) in OLE participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Eligible DB study participants were offered the opportunity to receive gantenerumab up-titrated to 1,200\u200amg Q4W. Safety and tolerability were assessed using magnetic resonance imaging (MRI), physical and neurologic examinations, and adverse event monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Overall, 225 participants were rolled over from the DB part of MR and received \u22651 gantenerumab dose in the OLE. The median treatment duration was 123 weeks. Fifty-nine (26.2%) and 41 (18.2%) participants had amyloid-related imaging abnormality (ARIA)-edema and ARIA-hemorrhage MRI findings, respectively. ARIA findings were manageable with MRI monitoring and dose intervention; most were asymptomatic. There were no unexpected safety findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>SC gantenerumab at doses of up to 1,200\u200amg Q4W were well tolerated in participants with mild AD dementia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/jad-240221","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T10:59:49Z","timestamp":1724151589000},"page":"353-367","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-Term Safety of Gantenerumab in Participants with Alzheimer\u2019s Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)"],"prefix":"10.1177","volume":"101","author":[{"given":"Anuja","family":"Neve","sequence":"first","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibha","family":"Das","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Wojtowicz","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyue","family":"Huang","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szofia","family":"Bullain","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Watkin","sequence":"additional","affiliation":[{"name":"Roche Products Limited, Welwyn Garden City, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Lott","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Bittner","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"},{"name":"Genentech, Inc., South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Delmar","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Klein","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Hofmann","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey A.","family":"Kerchner","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Smith","sequence":"additional","affiliation":[{"name":"Roche Products Limited, Welwyn Garden City, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Baudler","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Fontoura","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle S.","family":"Doody","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"},{"name":"Genentech, Inc., South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,8,17]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12328"},{"key":"ref002","unstructured":"World Health Organization (WHO). Dementia fact sheet, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia (2023, accessed 19 October 2023)."},{"key":"ref003","unstructured":"World Health Organization (WHO). The top 10 causes of death, http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death (2020, accessed 19 October 2023)."},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32205-4"},{"key":"ref005","first-page":"109","volume":"4","author":"Cummings J","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0318-y"},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa395"},{"key":"ref008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705971"},{"key":"ref012","first-page":"197","volume":"9","author":"Budd Haeberlein S","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2909"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304839"},{"key":"ref015","first-page":"S42","volume":"5","author":"Budd Haeberlein S","year":"2018","journal-title":"J Prev Alzheimers Dis"},{"key":"ref016","first-page":"264","volume":"4","author":"Doody R","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2011-110977"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.0c00364"},{"key":"ref019","unstructured":"ClinicalTrials.gov. A Study of Gantenerumab in Participants With Prodromal Alzheimer\u2019s Disease (Scarlet Road), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01224106 (2023, accessed 19 October 2023)."},{"key":"ref020","unstructured":"ClinicalTrials.gov. A Study of Gantenerumab in Participants With Mild Alzheimer Disease, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02051608 (2023, accessed 19 October 2023)."},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2535"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.54"},{"key":"ref023","first-page":"146","volume":"7","author":"Aisen PS","year":"2020","journal-title":"J Prev Alzheimers Dis"},{"key":"ref024","first-page":"S10","volume":"9","author":"Bateman R","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.11.015"},{"key":"ref026","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A3475"},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12376"},{"key":"ref028","first-page":"3","volume":"8","author":"Klein G","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"ref029","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0559-z"},{"key":"ref030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304430"},{"key":"ref031","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2019.04.690"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.1002\/alz.061840"},{"key":"ref033","doi-asserted-by":"publisher","DOI":"10.1002\/alz.063261"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-240221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JAD-240221","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-240221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:58:52Z","timestamp":1777370332000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JAD-240221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,8,27]]}},"alternative-id":["10.3233\/JAD-240221"],"URL":"https:\/\/doi.org\/10.3233\/jad-240221","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,17]]}}}